Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
about
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Interleukin-28B polymorphisms and response of chronic hepatitis C patients from Indonesia to pegylated interferon/ribavirin treatmentIdentification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients.Revisiting the stopping rule for hepatitis C genotype 1 patients treated with peginterferon plus ribavirin.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected egyptian patients using data mining analysisEfficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy.Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients.Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b.Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan.Association of IL28B SNPs rs12979860 and rs8099917 on Hepatitis C Virus-RNA Status in Donors/Recipients of Living Donor Liver Transplantation.Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial.Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotypeHost genetic variants in the pathogenesis of hepatitis C.Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C.Baseline high viral load and unfavorable patterns of alanine aminotransferase change predict virological relapse in patients with chronic hepatitis C genotype 1 or 2 obtaining rapid virological response during antiviral therapy.Genetic variants in interferon-λ 4 influences HCV clearance in Chinese Han population.Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapyIndividualization of chronic hepatitis C treatment according to the host characteristics.Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients.IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.Host factors determining the efficacy of hepatitis C treatment.Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.25-Hydroxy vitamin D suppresses hepatitis C virus replication and contributes to rapid virological response of treatment efficacy.Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearanceThe treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience.The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80 % full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial.The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection.Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics.Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.APASL consensus statements and recommendation on treatment of hepatitis C.Natural history of hepatitis C in thalassemia major: a long-term prospective study.
P2860
Q30250088-72857A31-D55D-42C5-869D-B1E5FEAAD1B1Q33559298-9874A52B-F7C6-4D41-B39C-9DC76601A531Q33703323-73E337D9-D0F1-49C6-BFD1-3326C0DAA05CQ33765497-0C5925DC-ECEE-4079-A370-67EB901225ACQ33783711-F3C6BE2F-617B-49FB-B3D6-77E3EF91E70FQ34532854-D4516122-C906-490C-A3E9-7A3C7380E37AQ34539324-630164C8-E8C4-4FD3-ACDC-020A90AB2788Q34634369-E796851C-358B-4EA7-81C5-2985B52EC563Q34996891-EB397EB9-DE28-490E-9560-A61C4913E855Q35131583-87A60D0C-BA76-4EBC-B148-730CCCD0094FQ35773677-6F66E373-A111-4EED-8B0A-7A5A8EB192A5Q35803105-F90DECFD-87E4-4C14-9B92-DB09ABA76013Q35870807-5CC4BAE8-2C3A-4BA9-A705-910DA2A535E3Q36009124-38AD6ECA-A75C-4BAE-985C-EED7A293EACCQ36044806-AAA47769-F7D0-4627-9811-2598457A2EB4Q36163864-FB5818D2-6598-4EB3-AC37-D2966B1CDDFDQ36226495-B4A38CC6-75CF-4295-B6FD-C0BAACDC7E63Q36482742-F6030480-B0FB-44E1-87F9-ADE1B690028FQ36675098-23C57750-2109-4F00-93BF-48DAA873742AQ37347763-7A7013F8-8B41-42BC-AC16-4FDA0B3CF86AQ37635067-EF9C3BDB-03B8-4AF8-B87A-5E1336F40929Q37641605-D96EC9CA-A689-4878-AE99-96A5754EDEBDQ37654502-86EFB66B-D5F0-4207-81EA-1657E4A06E4BQ38011758-0A88BCF5-2D52-4923-994B-FD5B863CD92AQ38053543-E2DA582A-CE63-4489-AF69-290ED09FDDAFQ38056077-312FB706-41B7-4E92-A479-451EF767CD48Q38459012-56497D8F-603C-4F76-85DC-4EF884D79561Q38477511-3396A426-EEA0-4F42-AFE0-56C58F6F8290Q38826138-AEFFEAA9-2B0C-4CFF-A5A4-7557A6FCB14CQ39104215-3C6CE673-6CE6-48D3-8A8D-F79ED4964BB3Q40322180-48940138-75E9-467A-915D-E04DCABAD26BQ40350424-3FCD8DA8-ACD5-4D8E-B55E-A174FD41BE88Q40694971-03D02E05-DA46-4D7D-A264-4192E70D38D9Q40706760-28F83C7C-BBF8-43D5-921E-AED501E77A66Q41493589-8D11E359-B1DE-4602-B5C6-628D866AA7CEQ42228388-877366AA-86B0-48AF-9273-3ED91457A1FAQ42249972-9CEBEB95-40F2-4376-9A2B-4659B552A9D7Q42285764-42000472-AF4B-4686-ACD9-63AF19D3D6FEQ42400012-74DD948D-7B1E-4A2E-B71C-3A64CF3406B3Q42989273-630BF46A-7E4C-409C-983A-332C5BAA7735
P2860
Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Interleukin-28B genetic varian ...... weeks peginterferon/ribavirin.
@en
Interleukin-28B genetic varian ...... weeks peginterferon/ribavirin.
@nl
type
label
Interleukin-28B genetic varian ...... weeks peginterferon/ribavirin.
@en
Interleukin-28B genetic varian ...... weeks peginterferon/ribavirin.
@nl
prefLabel
Interleukin-28B genetic varian ...... weeks peginterferon/ribavirin.
@en
Interleukin-28B genetic varian ...... weeks peginterferon/ribavirin.
@nl
P2093
P1476
Interleukin-28B genetic varian ...... weeks peginterferon/ribavirin.
@en
P2093
Chia-Yen Dai
Chung-Feng Huang
Hsing-Tao Kuo
Jee-Fu Huang
Jeng-Fu Yang
Ku-Chung Chen
Liang-Yen Wang
Ming-Lung Yu
Ming-Yen Hsieh
Shinn-Cherng Chen
P356
10.1016/J.JHEP.2011.03.029
P577
2011-05-19T00:00:00Z